English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

According to GLOBOCAN database for 2018, 637,761 (48.7%) new gynecologic cancer cases and 305,000 (50.1%) gynecologic cancer deaths were observed in Asia [1]. The difference between Asian women and non-Asians concerning genetic background, cancer epidemiology, disease characteristic, and socio-cultural environment has been well recognized. However, most of the experimental evidence to guide clinical gynecologic oncology practice have traditionally been derived from studies in western population. Asian Society of Gynecologic Oncology (ASGO) was founded in 2008 as the principal organization in Asia contributing to the study, prevention, and treatment of gynecological cancer by means of scientific exchange, regional/international collaboration, provision of educational opportunities, and strengthening friendship among members [2]. Currently, ASGO has members in over 10 countries in Asia.

The 6th Biennial Meeting of the Asian Society of Gynecologic Oncology, October 10th to 12th, 2019